SRR650180
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.620
- G2M_CHECKPOINT+0.560
- MYC_TARGETS_V1+0.540
- MYC_TARGETS_V2+0.520
- MTORC1_SIGNALING+0.400
- DNA_REPAIR+0.380
- INTERFERON_ALPHA_RESPONSE+0.310
- UNFOLDED_PROTEIN_RESPONSE+0.310
- SPERMATOGENESIS+0.270
- GLYCOLYSIS+0.260
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.490
- PANCREAS_BETA_CELLS-0.430
- ANGIOGENESIS-0.420
- BILE_ACID_METABOLISM-0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- COAGULATION-0.380
- TNFA_SIGNALING_VIA_NFKB-0.380
- UV_RESPONSE_DN-0.380
- TGF_BETA_SIGNALING-0.370
- KRAS_SIGNALING_UP-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613729 | — | E | 0.911 |
| 2 | MNG95 | — | — | 0.887 |
| 3 | TCGA-58-A46M-01A-11R-A24H-07 | — | cohortSQ2 | 0.887 |
| 4 | 504282dd-4fef-4f70-a709-6a545d00a263 | — | — | 0.873 |
| 5 | SRR8518395 | — | E | 0.861 |
| 6 | SRR33532767 | — | E | 0.859 |
| 7 | BS_DFGS950G | high-grade glioma | — | 0.858 |
| 8 | SRR8613807 | — | E | 0.851 |
| 9 | SRR23303750 | — | — | 0.851 |
| 10 | SRR8518323 | — | E | 0.850 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.620 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.540 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.520 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.380 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.310 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.310 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.270 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.230 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.210 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.060 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.030 | Remibrutinib | — uncovered |
| HYPOXIA | 0.010 | Idelalisib | — uncovered |